Custom Search


Login
MY ACCOUNT
WEBMAIL
GREYMAIL
paymybill_button
support_button
Not a customer? Click Here
Video
ADVERTISEMENT
Today's Health Headlines
CARACAS (Reuters) - Venezuela is investigating whether drug companies including Germany's Merck KGaA and Bayer AG have improperly profited from subsidized foreign exchange amid growing medicine shortages, the country's health minister said.

(Reuters) - Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases.

(Reuters Health) - Middle and high school students exposed to tobacco coupons were more likely to find smoking “cool” and less likely to feel confident in quitting if they already smoked, according to recent U.S. survey data.

LONDON (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet.

(Reuters) - Biopharma company Kymab said it had raised $50 million from two firms associated with veteran British investor Neil Woodford to support the privately held company's antibody-generating technology, Kymouse.

BEIJING (Reuters) - China has begun a new campaign against illegal prenatal gender tests and sex-selective abortions to help address the country's gender imbalance, state news agency Xinhua said on Wednesday.

CHICAGO (Reuters) - The U.S. government approved the use of an additional $330 million in emergency funds to help contain the worst avian influenza outbreak in U.S. history, as infected bird cases soared and hundreds of Minnesota poultry workers learned they would lose their jobs.

LONDON (Reuters) - European regulators do not agree with the negative view expressed by one adviser about the efficacy of UniQure's drug Glybera, the Western world's first gene therapy.

(Reuters) - Europe's medicines regulator said on Wednesday it would restrict experts and committee members who intend to work for a pharmaceutical company from participating in the evaluation of medicines, in a move to reduce conflict of interests.

NEW YORK (Reuters) - Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp's Watson computer system to choose therapies based on a tumor's genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients.

ADVERTISEMENT